Developer docs
API playgroundTry for free, no card

Search company profiles

Sudafed

Full company profile

uuid003ma14

Namestring
Sudafed
Legal namestring
Kenvue Brands LLC
Websiteurl
sudafed.com
Company typeenum
Public
Founded yearstring
-
Descriptiontext

Sudafed is a consumer health brand providing over-the-counter (OTC) relief from nasal and sinus congestion, sinus pressure, sinus headaches, and head congestion associated with the common cold, allergies, hay fever, and upper respiratory infections. The brand is owned and operated by Kenvue Brands LLC, a New Jersey-domiciled subsidiary of publicly traded Kenvue Inc. (NYSE: KVUE), which spun off from Johnson & Johnson in 2023. Sudafed's core technology rests on three small-molecule active pharmaceutical ingredients — pseudoephedrine HCl (behind-the-counter oral decongestant), phenylephrine HCl (open-shelf oral decongestant), and oxymetazoline HCl 0.05% (topical nasal spray) — delivered in tablets, caplets (immediate and 12-hour extended release), nasal sprays (including no-drip and cooling menthol formulations), saline nasal mists, and pediatric liquids for children aged 4+. The portfolio also features combination products pairing decongestants with acetaminophen, ibuprofen, naproxen sodium, guaifenesin, and dextromethorphan for multi-symptom relief.

The business model is one-time retail purchase of OTC pharmaceutical SKUs distributed through U.S. retail pharmacies and drug stores. Pseudoephedrine-containing products are sold behind the pharmacy counter under the federal Combat Methamphetamine Epidemic Act (CEMA) of 2006, requiring photo ID and monthly purchase limits, while phenylephrine, oxymetazoline, and saline SKUs are sold on open shelves. Sudafed targets a horizontal consumer base — adults with cold, allergy, and sinus symptoms, plus parents of children aged 4+ — through content marketing on sudafed.com, social media, email/rewards programs (available to Nevada and Washington residents), coupons, and in-store pharmacist consultation. The brand is marketed as the #1 pharmacist recommended OTC oral decongestant with 60+ years of continuous market presence.

Sudafed's strategic posture is defined by a dual-API hedge (pseudoephedrine plus phenylephrine) to navigate shifting regulatory landscapes, expansion into topical (oxymetazoline) and non-medicated (saline) adjacencies, and a children's sub-line that broadens the household buyer base. The brand is now exposed to a material regulatory event: the FDA's November 8, 2024 proposed order to remove oral phenylephrine from the OTC monograph, which would affect a substantial share of the SUDAFED PE® product family unless the order is reversed or modified in the final rulemaking.

Short descriptiontext

Sudafed is an over-the-counter nasal decongestant brand owned by Kenvue Inc., offering pseudoephedrine, phenylephrine, oxymetazoline, and saline products for adults and children with cold, allergy, and sinus symptoms sold through U.S. retail pharmacies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
Markets served

Serves global market

Keyword5 values
nasal decongestants, OTC cold medicine, sinus congestion relief, pharmacy retail products, pediatric decongestants
Industry5 codes
PRIMARYHLAIADAB
Cold, Flu & Cough Remedies
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAC
Allergy, Sinus & Respiratory (Non-Asthma)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYCRADAMAC
OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
OTC Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1OTC Pharmaceutical Retail Sales
TypeOne Time License
Description

Sudafed generates revenue through one-time retail purchases of OTC decongestant products sold through pharmacies, drug stores, and retail outlets. Products are available in multiple formulations including tablets, caplets, nasal sprays, and liquids targeting consumers with cold, allergy, and sinus congestion symptoms.

sudafed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Supply Chain, Marketing or Sales, Operations, Personnel
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sudafed sells over-the-counter nasal decongestant medications for relief of sinus and head congestion, common cold, and allergy symptoms. The portfolio spans oral tablets and caplets, medicated nasal sprays, saline nasal mist, and children's liquids across SUDAFED® (pseudoephedrine HCl, behind-the-counter), SUDAFED PE® (phenylephrine HCl, OTC shelves), and SUDAFED® OM (oxymetazoline HCl nasal spray) lines. Products are distributed through U.S. retail pharmacies and drug stores.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Starts working in seconds for nasal sprays
+2 more records
Product overview1 text field

Sudafed is a comprehensive over-the-counter (OTC) nasal decongestant brand offering both behind-the-counter (pseudoephedrine-based) and OTC (phenylephrine-based and oxymetazoline-based) products. The portfolio includes oral tablets and caplets (SUDAFED® and SUDAFED PE® lines), nasal sprays (SUDAFED® OM line with oxymetazoline), saline nasal mists, and children's liquid formulations. Key product families include: (1) SUDAFED® products with pseudoephedrine HCl requiring pharmacy counter purchase, available as immediate-release tablets (30 mg) and extended-release caplets (120 mg 12-hour); (2) SUDAFED PE® products with phenylephrine available OTC, including sinus pressure/pain relief, head congestion formulations, and day/night options; (3) SUDAFED® OM medicated nasal sprays with oxymetazoline HCl (0.05%) offering fast-acting 12-hour relief in original and cooling menthol no-drip formulations; (4) Non-medicated saline nasal spray with aloe for moisturizing; (5) Children's liquid decongestants in various flavors. The brand is marketed as the #1 pharmacist recommended oral OTC decongestant brand.

Product and service1 record
1SUDAFED® Sinus Congestion 12 Hour Relief Maximum Strength Decongestant Caplets
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Xlear sells xylitol-based saline nasal sprays and sinus care products, competing in the non-medicated nasal spray segment alongside Sudafed's saline mist with aloe.

TypeBroad incumbent
Description

Tylenol (Johnson & Johnson) extends its acetaminophen franchise into cold, flu, and sinus combination products, directly competing with Sudafed's phenylephrine-plus-acetaminophen SKUs.

TypeDirect peer
Description

Afrin (Bayer) markets oxymetazoline-based nasal decongestant sprays, the same active ingredient and dosage form used in Sudafed's OM nasal-spray line, making it the closest direct competitor in topical nasal decongestion.

TypeBroad incumbent
Description

Vicks (Procter & Gamble / Haleon) is a heritage multi-symptom cold and flu brand (NyQuil, DayQuil, VapoRub, Formula 44) that overlaps Sudafed in cold/sinus/cough remedies across U.S. retail shelves.

TypeBroad incumbent
Description

Zyrtec (Kenvue, Sudafed's sister brand) is a top OTC antihistamine; both brands live under Kenvue Brands LLC and target overlapping allergy/sinus symptom occasions.

TypeDirect peer
Description

Mucinex (Reckitt) is a leading U.S. OTC brand for chest congestion, cough, and sinus/cold symptom relief, including guaifenesin expectorants and combination decongestant SKUs sold in similar retail-pharmacy channels.

TypeDirect peer
Description

NeilMed specializes in saline nasal irrigation (sinus rinse bottles, saline sprays) — overlapping with Sudafed's saline nasal mist line and competing for consumers seeking drug-free congestion relief.

8Claritin
TypeBroad incumbent
Description

Claritin (Bayer) is a leading OTC non-drowsy antihistamine for allergies; it competes with Sudafed's allergy/sinus use cases via a different mechanism and is an alternative rather than a substitute in many congestion journeys.

TypeBroad incumbent
Description

Advil/Aleve-D (Haleon/Bayer) offer ibuprofen- and naproxen-based decongestant combinations that overlap with Sudafed PE Pressure + Pain and 12-Hour Pressure + Pain caplets on the same retail shelves.

10Robitussin
TypeBroad incumbent
Description

Robitussin (Haleon) is a major OTC cough, cold, and chest-congestion brand that competes with Sudafed's multi-symptom tablets and Children's PE Cough + Cold SKU.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sudafed

OTC Pharmaceuticalssudafed.com

Sudafed is an over-the-counter nasal decongestant brand owned by Kenvue Inc., offering pseudoephedrine, phenylephrine, oxymetazoline, and saline products for adults and children with cold, allergy, and sinus symptoms sold through U.S. retail pharmacies.

What Sudafed does

Sudafed is a consumer health brand providing over-the-counter (OTC) relief from nasal and sinus congestion, sinus pressure, sinus headaches, and head congestion associated with the common cold, allergies, hay fever, and upper respiratory infections. The brand is owned and operated by Kenvue Brands LLC, a New Jersey-domiciled subsidiary of publicly traded Kenvue Inc. (NYSE: KVUE), which spun off from Johnson & Johnson in 2023. Sudafed's core technology rests on three small-molecule active pharmaceutical ingredients — pseudoephedrine HCl (behind-the-counter oral decongestant), phenylephrine HCl (open-shelf oral decongestant), and oxymetazoline HCl 0.05% (topical nasal spray) — delivered in tablets, caplets (immediate and 12-hour extended release), nasal sprays (including no-drip and cooling menthol formulations), saline nasal mists, and pediatric liquids for children aged 4+. The portfolio also features combination products pairing decongestants with acetaminophen, ibuprofen, naproxen sodium, guaifenesin, and dextromethorphan for multi-symptom relief.

The business model is one-time retail purchase of OTC pharmaceutical SKUs distributed through U.S. retail pharmacies and drug stores. Pseudoephedrine-containing products are sold behind the pharmacy counter under the federal Combat Methamphetamine Epidemic Act (CEMA) of 2006, requiring photo ID and monthly purchase limits, while phenylephrine, oxymetazoline, and saline SKUs are sold on open shelves. Sudafed targets a horizontal consumer base — adults with cold, allergy, and sinus symptoms, plus parents of children aged 4+ — through content marketing on sudafed.com, social media, email/rewards programs (available to Nevada and Washington residents), coupons, and in-store pharmacist consultation. The brand is marketed as the #1 pharmacist recommended OTC oral decongestant with 60+ years of continuous market presence.

Sudafed's strategic posture is defined by a dual-API hedge (pseudoephedrine plus phenylephrine) to navigate shifting regulatory landscapes, expansion into topical (oxymetazoline) and non-medicated (saline) adjacencies, and a children's sub-line that broadens the household buyer base. The brand is now exposed to a material regulatory event: the FDA's November 8, 2024 proposed order to remove oral phenylephrine from the OTC monograph, which would affect a substantial share of the SUDAFED PE® product family unless the order is reversed or modified in the final rulemaking.

Sudafed firmographics

Firmographics
Name
Sudafed
Legal name
Kenvue Brands LLC
Website
https://sudafed.com
Company type
Public
Operating status
Operating
Headcount range
51–100 employees
Short description
Sudafed is an over-the-counter nasal decongestant brand owned by Kenvue Inc., offering pseudoephedrine, phenylephrine, oxymetazoline, and saline products for adults and children with cold, allergy, and sinus symptoms sold through U.S. retail pharmacies.
Ownership category
akta.pro rank

Sudafed industry classification

Industry
Product category
OTC Pharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIADAB
Cold, Flu & Cough Remedies
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIADAC
Allergy, Sinus & Respiratory (Non-Asthma)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYCRADAMAD
Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYCRADAMAC
OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Nasal decongestants
  • OTC cold medicine
  • Sinus congestion relief
  • Pharmacy retail products
  • Pediatric decongestants

Sudafed business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Operations, Personnel

Revenue model

  1. OTC Pharmaceutical Retail Sales: Sudafed generates revenue through one-time retail purchases of OTC decongestant products sold through pharmacies, drug stores, and retail outlets. Products are available in multiple formulations including tablets, caplets, nasal sprays, and liquids targeting consumers with cold, allergy, and sinus congestion symptoms.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Sudafed product offering

Product offering

Core offering

Sudafed sells over-the-counter nasal decongestant medications for relief of sinus and head congestion, common cold, and allergy symptoms. The portfolio spans oral tablets and caplets, medicated nasal sprays, saline nasal mist, and children's liquids across SUDAFED® (pseudoephedrine HCl, behind-the-counter), SUDAFED PE® (phenylephrine HCl, OTC shelves), and SUDAFED® OM (oxymetazoline HCl nasal spray) lines. Products are distributed through U.S. retail pharmacies and drug stores.

Product overview

Sudafed is a comprehensive over-the-counter (OTC) nasal decongestant brand offering both behind-the-counter (pseudoephedrine-based) and OTC (phenylephrine-based and oxymetazoline-based) products. The portfolio includes oral tablets and caplets (SUDAFED® and SUDAFED PE® lines), nasal sprays (SUDAFED® OM line with oxymetazoline), saline nasal mists, and children's liquid formulations. Key product families include: (1) SUDAFED® products with pseudoephedrine HCl requiring pharmacy counter purchase, available as immediate-release tablets (30 mg) and extended-release caplets (120 mg 12-hour); (2) SUDAFED PE® products with phenylephrine available OTC, including sinus pressure/pain relief, head congestion formulations, and day/night options; (3) SUDAFED® OM medicated nasal sprays with oxymetazoline HCl (0.05%) offering fast-acting 12-hour relief in original and cooling menthol no-drip formulations; (4) Non-medicated saline nasal spray with aloe for moisturizing; (5) Children's liquid decongestants in various flavors. The brand is marketed as the #1 pharmacist recommended oral OTC decongestant brand.

Differentiator

Problem solved

Functional benefit

Products and services

  • SUDAFED® Sinus Congestion 12 Hour Relief Maximum Strength Decongestant Caplets

Quantifiable outcome

  • Starts working in seconds for nasal sprays
  • +2 more outcomes

Companies that use Sudafed

Customer profile

Segments2 records

Ideal customer profiles2 records

Sudafed technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sudafed partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Sudafed competitors and assessment

Company assessment

Emerging players

  • Xlear: Xlear sells xylitol-based saline nasal sprays and sinus care products, competing in the non-medicated nasal spray segment alongside Sudafed's saline mist with aloe.

Broad incumbents

  • Tylenol Cold & Flu / Tylenol Sinus: Tylenol (Johnson & Johnson) extends its acetaminophen franchise into cold, flu, and sinus combination products, directly competing with Sudafed's phenylephrine-plus-acetaminophen SKUs.
  • Vicks: Vicks (Procter & Gamble / Haleon) is a heritage multi-symptom cold and flu brand (NyQuil, DayQuil, VapoRub, Formula 44) that overlaps Sudafed in cold/sinus/cough remedies across U.S. retail shelves.
  • Zyrtec: Zyrtec (Kenvue, Sudafed's sister brand) is a top OTC antihistamine; both brands live under Kenvue Brands LLC and target overlapping allergy/sinus symptom occasions.
  • Claritin: Claritin (Bayer) is a leading OTC non-drowsy antihistamine for allergies; it competes with Sudafed's allergy/sinus use cases via a different mechanism and is an alternative rather than a substitute in many congestion journeys.
  • Advil Cold & Sinus / Aleve-D: Advil/Aleve-D (Haleon/Bayer) offer ibuprofen- and naproxen-based decongestant combinations that overlap with Sudafed PE Pressure + Pain and 12-Hour Pressure + Pain caplets on the same retail shelves.
  • Robitussin: Robitussin (Haleon) is a major OTC cough, cold, and chest-congestion brand that competes with Sudafed's multi-symptom tablets and Children's PE Cough + Cold SKU.

Direct peers

  • Afrin: Afrin (Bayer) markets oxymetazoline-based nasal decongestant sprays, the same active ingredient and dosage form used in Sudafed's OM nasal-spray line, making it the closest direct competitor in topical nasal decongestion.
  • Mucinex: Mucinex (Reckitt) is a leading U.S. OTC brand for chest congestion, cough, and sinus/cold symptom relief, including guaifenesin expectorants and combination decongestant SKUs sold in similar retail-pharmacy channels.
  • NeilMed Pharmaceuticals: NeilMed specializes in saline nasal irrigation (sinus rinse bottles, saline sprays) — overlapping with Sudafed's saline nasal mist line and competing for consumers seeking drug-free congestion relief.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Sudafed social profiles

Digital presence

Sudafed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sudafed leadership team

Management profile

Number of profiles

Sudafed funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sudafed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sudafed

What does Sudafed do?

Sudafed sells over-the-counter nasal decongestant medications for relief of sinus and head congestion, common cold, and allergy symptoms. The portfolio spans oral tablets and caplets, medicated nasal sprays, saline nasal mist, and children's liquids across SUDAFED® (pseudoephedrine HCl, behind-the-counter), SUDAFED PE® (phenylephrine HCl, OTC shelves), and SUDAFED® OM (oxymetazoline HCl nasal spray) lines. Products are distributed through U.S. retail pharmacies and drug stores.

Is Sudafed a public or private company?

Sudafed is a public company. It is classified as corporate owned and is currently operating.

When was Sudafed founded?

Sudafed was founded in -1. It employs 51 to 100 people.

How does Sudafed make money?

One revenue line is on record: OTC Pharmaceutical Retail Sales.

Who are Sudafed's main competitors?

Xlear is listed as an emerging player. Broad incumbents are Tylenol Cold & Flu / Tylenol Sinus, Vicks, Zyrtec, Claritin, Advil Cold & Sinus / Aleve-D and Robitussin. Direct peers are Afrin, Mucinex and NeilMed Pharmaceuticals.

Does Sudafed have an API?

No public API is recorded for Sudafed.

What industry is Sudafed in?

Sudafed's product category is OTC Pharmaceuticals. Its primary akta.pro industry code is HLAIADAB, Cold, Flu & Cough Remedies, with a secondary code of HLAIADAC, Allergy, Sinus & Respiratory (Non-Asthma). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BBCDynes yn gaeth i Sudafed am ddegawd ac wedi gwario miloeddLouise Gough, 30, spent over 10 years using Sudafed nasal sprays, spending about £2,000 on them. She became dependent, feeling trapped, and now uses them only when needed. The company says its products follow strict regulations.BBCCaerphilly woman gets addicted to nasal spray after missing warningLouise Gough, 30, from Caerphilly, became addicted to Sudafed nasal spray after missing the short-term-use warning, using it up to 15 times daily. She spent about £2,000 on secret bottles and developed rebound congestion, quitting three years ago. She still has not fully regained her sense of taste and smell.GlobeNewswireNeed a Re-Do? With a SUDAFED REPLAY(TM) Sinus Sufferers Have the Chance to Experience a Missed Activity Without Pain & CongestionSUDAFED is offering a SUDAFED REPLAY sweepstakes where sinus sufferers can enter to win a $250 gift card for a flight, sporting event, or movie replay. The sweepstakes runs through April 6, 2014, with winners announced on March 19, April 2, and April 19. A survey found 44% of sufferers are uncomfortable flying with sinus pain.GlobeNewswireSUDAFED(R) Brand Unveils First-of-Its-Kind SINUS SKETCHER(TM) App to Help Sinus Sufferers Open Up Through DrawingSUDAFED launched the SINUS SKETCHER app for a Facebook contest where sinus sufferers submit sketches illustrating their pain. The contest runs until November 24, with a $5,000 prize and a national ad campaign. A survey found 53% of adults frequently experience sinus pain, and 81% would sacrifice everyday pleasures to avoid it.